Resmed (RSMDF) Current Deferred Revenue (2010 - 2026)

Resmed has reported Current Deferred Revenue for 17 years, with the latest figure at $179.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 11.74% year-over-year to $179.3 million; the trailing twelve-month figure through Mar 2026 stood at $179.3 million (up 11.74% YoY), and the FY2025 full-year result was $166.0 million, up 8.83% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $179.3 million, up from $176.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $179.3 million in Q1 2026, with the low at $108.2 million in Q3 2022.
• Historically, Current Deferred Revenue has averaged $147.3 million across 5 years, with a median of $150.8 million in 2024.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue fell 3.85% — and 2023, when it surged 35.61%.
• Resmed's Current Deferred Revenue stood at $133.9 million in 2022, then advanced by 11.19% to $148.9 million in 2023, then grew by 5.11% to $156.5 million in 2024, then increased by 12.49% to $176.0 million in 2025, then grew by 1.83% to $179.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $179.3 million (Q1 2026), $176.0 million (Q4 2025), and $167.8 million (Q3 2025), per Business Quant data.